LIPITOR

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Canada, Cyprus, Ecuador, Finland, Germany, Hong Kong SAR China, Ireland, Israel, Japan, Malta, Mexico, Netherlands, New Zealand, Nigeria, Singapore, South Africa, Turkey, UK.

Active ingredients

The drug LIPITOR contains one active pharmaceutical ingredient (API):

1	Atorvastatin UNII 48A5M73Z4Q - ATORVASTATIN CALCIUM TRIHYDRATE
	Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.
	Read more about Atorvastatin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LIPITOR Film-coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
LIPITOR Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AA05	Atorvastatin	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors
Discover more medicines within C10AA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8213G, 8214H, 8215J, 8521L, 9230T, 9231W, 9232X, 9233Y
BR	Câmara de Regulação do Mercado de Medicamentos	552820020061917, 552820020062017, 552820020062117, 552820020062217, 552820020062317, 552820020062417, 552820020062517, 552820020062617, 552820020062717
CA	Health Products and Food Branch	02230711, 02230713, 02230714, 02243097
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	07639372
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	2357-MEE-0716, 2484-MEE-1216, H5000513, H5240513
FI	Lääkealan turvallisuus- ja kehittämiskeskus	061527, 061538, 061550, 061561, 061584, 061595, 061607, 550124
GB	Medicines & Healthcare Products Regulatory Agency	13376, 13390, 13397, 139228, 139231, 139234, 143111, 161997, 18799, 197194, 197197, 198752
HK	Department of Health Drug Office	42328, 42329, 42330, 49653
IE	Health Products Regulatory Authority	31710, 31731, 31752, 31798, 31819, 31892, 32001, 32038, 32359, 32363, 32399, 32551, 41884, 41885
IL	מִשְׂרַד הַבְּרִיאוּת	4076, 4077, 4562, 4563
JP	医薬品医療機器総合機構	2189015F1023, 2189015F2020
MT	Medicines Authority	MA1396/00901, MA1396/00902, MA1396/00903, MA1396/00904, MA1396/00905, PI770/12701A
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	413M97
NG	Registered Drug Product Database	04-3158, 04-3159, 04-3160, A4-5732
NL	Z-Index G-Standaard, PRK	98604, 98612, 98620, 98779, 98787
NZ	Medicines and Medical Devices Safety Authority	14310, 14311, 14312, 14313
SG	Health Sciences Authority	09550P, 09551P, 09552P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699532090201, 8699532091420, 8699532091475, 8699532094964, 8699532095015, 8699532095190, 8699532095541, 8699532095619
US	FDA, National Drug Code	0071-0155, 0071-0156, 0071-0157, 0071-0158, 55289-800, 55289-861, 55289-870, 63629-1446, 63629-6633, 63629-6768, 63629-6776
ZA	Health Products Regulatory Authority	31/7.5/0357, 31/7.5/0358, 31/7.5/0359, 37/7.5/0210